<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is characterized by obstetric and thrombotic complications in the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It can happen in an isolated way or in association with diffuse <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e>, mainly <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The association of APS with <z:e sem="disease" ids="C0039263" disease_type="Disease or Syndrome" abbrv="">Takayasu</z:e> <z:hpo ids='HP_0012089'>arteritis</z:hpo> (TA) is rarely described in the literature </plain></SENT>
<SENT sid="3" pm="."><plain>We described a case of primary APS in a female patient who developed obstruction in large-size arteries, in spite of the use of oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, and increase of erythrocyte sedimentation rate, suggesting TA </plain></SENT>
<SENT sid="4" pm="."><plain>The favorable response to <z:chebi fb="0" ids="8382">prednisone</z:chebi> treatment and later to infliximab reinforced the diagnosis of TA </plain></SENT>
<SENT sid="5" pm="."><plain>The present report illustrates the existence of APS associated to TA, whose recognition is very important once the therapeutic strategy is radically different </plain></SENT>
</text></document>